1. The release of growth hormone from isolated fragments of rat anterior pituitary tissue incubated in vitro was studied by employing a double-antibody radioimmunoassay. 2. In the absence of added stimuli, two phases of hormone release could be distinguished, an early phase of 2h duration and a subsequent late phase. In the early phase, hormone release was rapid but could be significantly decreased by calcium depletion and by 2,4-dinitrophenol whereas the rate ofrelease in the late phase was uninfluenced by these incubation conditions. These results have been interpreted as indicating the existence of a secretory component in the early phase of release. 3. In subsequent experiments, the effects of various agents on the rate ofhormone output during the late phase ofincubation were investigated. Hormone release was increased by theophylline and by dibutyryl cyclic AMP (N6-2'-O-dibutyryl-adenosine 3': 5'-cyclic monophosphate), the response to both of these agents being related to the concentration of the stimulant employed. 4. The stimulation of growth hormone output by theophylline was significantly decreased by calcium deprivation and by 2,4-dinitrophenol. The response to dibutyryl cyclic AMP was diminished by 2,4-dinitrophenol, iodoacetate and 2-deoxyglucose but not by malonate or colchicine. 5. Arginine, ,-hydroxybutyrate, albumin-bound palmitate and variation in the glucose concentration of the incubation medium over a wide range were without any statistically significant effect on the rate of hormone release from either control pituitary fragments or those subject to secretory stimulation by dibutyryl cyclic AMP. 6. It is suggested that the regulation of growth hormone secretion is mediated by cyclic AMP (adenosine 3': 5'-cyclic monophosphate). The secretion observed in response to cyclic AMP requires the presence of ionized calcium and a source of metabolic energy but is independent of pituitary protein synthesis de novo. The integrity of the glycolytic pathway of glucose metabolism appears to be essential for cyclic AMP-stimulated growth hormone secretion to occur.
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Previous studies relating to the control of growth hormone secretion have led to the generally accepted view that, in man, the hormone is secreted in response to stress (Greenwood & Landon, 1966) , to hypoglycaemia (Roth, Glick, Yalow & Berson, 1963) and to elevations in the circulating concentrations of amino acids of which arginine appears to be the most effective (Merimee, Lillicrap & Rabinowitz, 1965) . Although the precise site of action of these stimuli remains uncertain, the observations that the growth hormone response to insulin-induced hypoglyeaemia may be abolished by section ofthe hypothalamo-pituitary stalk (Roth et al. 1963) , by certain hypothalamic lesions (Abrams, Parker, Blanco, Reichlin & Daughaday, 1964) and by micro-infusion of glucose directly into the hypothalamus (Blanco, Schalch & Reichlin, 1966) , suggest a probable mediation by nerve cells in this part of the central nervous system. This concept has received further support from the finding in mammalian hypothalamic extracts of a substance, the so-called growth hormone releasing factor, which is active in stimulating both the release and the synthesis of growth hormone by the somatotroph cells of the anterior pituitary (Deuben & Meites, 1964; Schally, Steelman & Bowers, 1965) . In studies of bovine pituitary slices in vitro, however, Schofield (1967a,b) demonstrated that a number of agents appeared to be capable of influencing growth hormone release by a direct effect on the pituitary gland itself. Amongst these findings was the report that theophylline, a methylxanthine which acts to inhibit the enzyme phosphodiesterase responsible for the inactivation of cyclic 815 AMP, leads to a significant acceleration of growth hormone release fromthispreparation. Subsequently, further evidence, obtained both in vivo (Muller, Pecile, Kabir Naimzada & Ferrario, 1969) and in vitro (Steiner, Peake, Utiger, Karl & Kipnis, 1970) , has confirmed the hypothesis, originally advanced by Schofield (1967b) , that cyclic AMP may be important in the mediation of the effect of growth hormone releasing factor. In addition, Steiner et al. (1970) showed that both theophylline and extracts of pituitary-stalk-median-eminence tissue led to an increase in growth hormone release from the isolated rat anterior pituitary which was accompanied by a parallel increase in the pituitary concentration of cyclic AMP.
The purpose of the present study was to devise a simple system in vitro, based on measurement of the rate of growth hormone release from isolated fragments of rat anterior pituitary, which would be suitable for the further investigation of the mechanisms by which growth hormone secretion may be controlled. The rat pituitary was chosen for these studies on grounds of its ready accessibility in the fresh state and its relatively small size which allows fragments to be obtained with miimal tissue damage. The investigations described below were made possible by the recent development in this laboratory of a rapid, sensitive and specific doubleantibody radioimmunoassay for rat growth hormone which has been shown to be valid when applied to the determination of the hormone released into media in which rat anterior pituitary fragments have previously been incubated.
In the present paper, evidence is presented to show that the rat pituitary fragment preparation provides a reproducible and sensitive system for the investigation in vitro of the regulation of growth hormone release and that, by its use, it is possible to distinguish between hormone leakage, occurring presumably from cells damaged during isolation of the gland fragments, and true secretion. The system has been employed to study growth hormone secretion and to investigate the metabolic requirements exhibited by the gland when it is in an actively secreting state. A preliminary account of some of the findings reported here, including the demonstration of a direct effect of the cyclic nucleotide in stimulating growth hormone secretion in vitro, has previously been published (Lockhart Ewart & Taylor, 1970 (Morgan & Lazarow, 1963) was employed in the immunoassay, which was carried out at room temperature.
Assay diluent buffer (100l,) was added to each assay tube followed by lOO,ul of anti-(rat growth hormone) serum at a dilution of 1:40000. This dilution of antiserum was sufficient to bind approx. 50% of the radioactivity associated with lOOpg of 125I-labelled rat growth hormone in the absence of competing unlabelled hormone under the conditions of the assay. A volume (lOOulI) of solutions containing standard or unknown concentrations of rat growth hormone was then added and the contents of each tube were mixed and incubated at room temperature for 2h. At the end of this period, 12Us-labelled rat growth hormone (approx. lOOpg) was added in a volume of IOO,ul and the incubation allowed to proceed at room temperature for 36h. Rhesus monkey serum (lOOul of a 1:500 dilution in assay diluent buffer) was then added to act as a carrier. Finally, lOO,ul of anti-(rhesus monkey y-globulin) serum was added at the dilution (1:3 in assay diluent buffer) which had previously been shown to produce optimum precipitation of the 1251-labelled rat growth hormone-antibody complex. Incubation at room temperature was then continued for 4 h after which the assay tubes were centrifuged at 1 5OOg for 20 min and the supernatants removed by using a Pasteur pipette. The precipitates were taken up in 10Oz1 of water, 1ml of the Triton scintillation mixture was added and, after thorough mixing, the radioactivity associated with the precipitates was assayed. (Gey & Gey, 1936) containing glucose (5.6 mM) as an energy source and bovine plasma albumin (1 mg/ml) to decrease adsorptive losses of the released growth hormone. In addition, the quantity of CaCl2 employed in making up the medium was modified to give a final Ca2+ concentration of 2 mm. The medium was thoroughly gassed with 02 +C02 (95:5) in the early phase of incubation, the preincubation period was decreased to 30 min. In both cases, after preincubation, the medium was discarded and the pituitary fragments were briefly washed with 1 ml of medium at 370C. Freshly prepared incubation medium (3 ml) containing the substances under investigation was then added to alternate flasks, the remaining flasks, which contained the paired fragments from the same gland, receiving an equal volume of control medium. Incubation was then continued for 1 h at 37°C and samples of the medium were taken for assay.
In experiments to determine the effects on release of metabolic inhibitors, the gland fragments were exposed to the inhibitor during the final hour of preincubation (or 30 min in studies of release in the early phase) as well as during the incubation proper. An exception to this is provided by iodoacetate which was added to the medium only during the incubation period itself since prolonged exposure to this agent has been reported to lead to a marked loss of its specificity as an inhibitor of the enzyme, triose phosphate dehydrogenase (Webb, 1966a) .
In experiments designed to investigate the effect of Ca2+ depletion on release, the gland fragments were exposed to Ca2+-free medium throughout the preincubation period and EDTA (0.5mM) was added to the incubation medium of the experimental fragments during both the final 30min of the preincubation and the experimental period itself. To exclude the possibility of a direct effect of the chelating agent in these experiments, EDTA (0.5mM) was also added to the control flasks during the same periods, normal Ca2+ concentration, 2 mm, being maintained by the addition of supplementary CaCl2 to the control medium.
At the conclusion of each incubation, samples of the medium were rapidly frozen in a mixture of acetone and solid C02 and stored at -20°C for up to 2 weeks until assayed. In each experiment, samples of all media employed were assayed to exclude the possibility of nonspecific interference in the assay by any of the added substances.
Application of the immunoassay to unknown solutions Preparation of samples. For assay of the growth hormone content of the anterior pituitary tissue, gland fragments of approx. 3mg wet wt. were homogenized singly in 2ml of 0.01 M-NaOH in an all-glass homogenizer and, after centrifugation at 2000g for 5min to remove particulate material, the supernatant was diluted 1:16000 in assay diluent buffer for assay. Incubation media were assayed at a dilution of 1:150 in the same buffer.
A8say specificity. In the protocol provided with the reagents supplied by the National Institute of Arthritis and Metabolic Diseases, it is reported that there is no interference in the assay from rat follicle-stimulating hormone, luteinizing hormone or thyroid-stimulating hormone but that rat prolactin shows a cross-reactivity of approx. 2%. In the present studies, evidence relating to the specificity of the assay was obtained by determining the growth hormone content of a sample of incubation medium over a range of doubling dilutions from 1:75 to 1:1200. The results indicated that the apparent total growth hormone content of the medium is independent of the dilution employed in the assay. This observation implies parallelism between the binding inhibition curves characteristic of the unknowns and the standard rat growth hormone preparation and provides evidence that there is a protein present in the incubation medium which is immunologically indistinguishable from the standard preparation of rat growth hormone employed in the assay.
Sensitivity and reproducibility of the as8ay. To assess the sensitivity of the assay when applied to unknown solutions, the results obtained in 105 consecutive assays, each performed in triplicate, of diluted incubation media were analysed by using the method proposed by Brown, Bulbrook & Greenwood (1957) . Calculated in this way, the quantitative sensitivity of the assay, defined as the least amount of growth hormone which can be measured with a maximum percentage error (P = 0.05) of ±50%, was 400pg-equiv. of NIAMD-Rat GH-RP-1, or approx.
lOOpg of rat growth hormone if allowance is made for the low potency of the standard employed.
The reproducibility of the assay was investigated by assaying a single sample of incubation medium on four separate occasions over a period of 3 weeks, the medium being separately diluted on each occasion. The mean concentration of rat growth hormone determined in the four assays was 31.0±2.9 (S.E.M.) ng/ml indicating a high degree of reproducibility of the method.
Stability of rat growth hormone. To investigate the stability of the hormone under conditions of incubation, 5,ug of the standard preparation of rat growth hormone (NIAMD-Rat GH-RP-1) was added to samples of incubation media in which pituitary fragments had previously been incubated and the growth hormone concentrations of which had already been determined. The media, together with the added growth hormone, were then exposed to a further period of 60min incubation at 370C and the total growth hormone content was assayed.
In these experiments, the mean recovery of the added hormone was 96.0±3.3 (s.E.M.)%.
The stability of the hormone under the conditions of the assay was assessed by means of a recovery experiment in which 5 ng of standard rat growth hormone was assayed in triplicate in the presence of dilutions of different unknowns. The measurements ofrecovery of the standard hormone obtained in the presence of dilutions of incubation media and pituitary homogenates were respectively 94.8±3.2% and 99.4±7.0% (mean±s.E.M.).
From these experiments it is concluded that rat growth hormone is stable under the conditions of both incubation and assay and that the results obtained provide an accurate reflexion of the hormonal content both of homogenates and incubation media. Calculation and expression of results. Characteristics of growth hormone release in the early and late phases of incubation. In an attempt to determine the nature of the hormone release observed in the early and late phases of incubation, a series ofexperiments was carried out to investigate the effects of varying the incubation conditions on the rate of hormone output characteristic of the two phases. The results of these experiments are shown in Table 1 , from which it can be seen that early phase release was significantly decreased both by 2,4-dinitrophenol (0.2mM) and by calcium depletion to values closely similar to those seen in the late-phase controls, whereas late-phase release itself was unaffected by these conditions of incubation. Conversely, on addition of theophylline (5mM) to the medium, the observed stimulatory effect was greater in the late phase (280% of control) than in the early phase (164% of control) although the absolute rates of release attained in each of the two phases were not significantly different (Table 1) . It was concluded from these findings that, during the early phase of incubation, the pituitary fragments in vitro were in an active secretory state (see the Discussion section) and, to ensure that the gland fragments were in a truly basal condition, all subsequent experiments were carried out with incubation for lh after a 2.5h period of preincubation.
Linearity of growth hormone release during incubation in vitro. To determine whether the products released into the medium lead to inhibition of further growth hormone release during the late phase of incubation, an experiment was performed in which the growth hormone content ofthe medium was determined at 20min intervals during incubation in the presence and absence of 5mM-theophylline. The results of this experiment, shown in Fig. 2 The results of this analysis are shown in Table 2 from which it can be seen that the observed rate of release/mg wet weight of tissue was inversely related to fragment size (of. Schofield, 1967a) . To avoid possible bias of the results in the subsequent experiments, therefore, it was important to ensure that the control and experimental fragments cut from a single gland were of very closely similar weight. In the studies described below, the weights of the pituitary fragments employed were maintained within the range 2-4mg.
Effect of 2,4-dinitrophenol, calcium deprivation and cycloheximide on growth hormone relea8e in the presence of theophylline. The results of these experiments are given in Table 3 from which it can be seen that theophylline exerts a significant stimulating effect on growth hormone release at both concentrations tested (0.5 and 5mm), the response observed being related to the concentration. In an attempt to establish the nature of this stimulation, a number of experiments was carried out to determine whether the response might be modified by alteration in the incubation conditions. Table 3 shows that the rate of growth hormone output in response to 0.5m -theophylline was significantly decreased both by 0.2mm-2,4-dinitrophenol (P<0.005) and by calcium deprivation (P<0.05) although the observed rates of release from the control fragments were unaltered by these incubation conditions. In the presence of cyclohexiimide (20,ug/ml), an inhibitor of protein synthesis, the observed rates ofgrowth hormone output from both the control and theophylline-stimulated fragments were increased, only the latter increase, however, attaining statistical significance. Despite these changes in the rates of hormone release, however, 1971 820 CYCLIC AMP AND GROWTH HORMONE SECRETION the response to 5 mM-theophylline was essentially unchanged by the inhibitor (Table 3) . Thus, the stimulation due to theophylline in the control fragments (321%) was not significantly different from that seen in the presence of cycloheximide (293%).
Effect of amino acids, variation in glucose concentration, L-fl-hydroxybutyrate, albumin-bound palmitate, cyclic AMP and dibutyryl cyclic AMP on growth hormone release. The results of these experiments are given in Table. 4. Both L-arginine hydrochloride and L-leucine, at a concentration of 5mM, regularly appeared to stimulate growth hormone release but the effects were small and did not attain statistical significance. Albumin-bound palmitate (0.6mM) and ,-hydroxybutyrate (5mM) were without demonstrable effect on the rate of hormone release and output was likewise unaffected by variations in the glucose concentration of the medium within the range from 2-20mM. Since the observed stimulating effect of theophylline (Tables  1 and 3 ) seemed most probably to be attributable to the action of this substance in potentiating the effects of endogenous intracellular cyclic AMP by inhibition of the phosphodiesterase normally responsible for its breakdown, we decided to investigate whether the cyclic nucleotide itself might exert a direct effect upon growth hormone release. In initial experiments, cyclic AMP (1 mM) was employed and this was found to be without a significant effect on growth hormone release in vitro (Table 4) . In later experiments, however, employing dibutyryl-cyclic AMP, it was possible to demonstrate a significant stimulation of hormone output in response to both concentrations of the derivative of the cyclic nucleotide tested (0.2 and 1 mM) and that, as in the case of theophylline, the response was related to the concentration employed.
Effect of L-arginine hydrochloride, variation in glucose concentration, L-,-hydroxybutyrate and albumin-bound palmitate on dibutyryl cyclic AMPstimulated growth hormone release. In view of the failure to demonstrate a significant direct effect of arginine, ,-hydroxybutyrate, albumin-bound palmitate or variation in the glucose concentration of the medium upon growth hormone release from pituitary fragments in a basal state (Table 4) , a further series of experiments was performed to investigate the effects of these incubation conditions on the stimulated release seen in the Table 4 . Effect of L-arginine hydrochloride, L-leucine, variations in gluco8e concentration, L-,-hydroxy. butyrate, albumin-bound palmitate, cyclic AMP and dibutyryl cyclic AMP on growth hormone release in vitro After preincubation for 2.5h, pituitary fragments were incubated for 1 h in 3ml of a bicarbonate-buffered medium. All media contained bovine plasma albumin (1 mg/ml) and glucose (5.6mM) except where otherwise stated and other additions to the medium were as shown. The results are expressed as the mean rates of hormone output (±s.x.m.) calculated for the number of observations in parentheses. Values of P for differences of the results from the appropriate control were calculated as described in the Materials and Methods section.
Rate of growth hormone release (,ug of NIAMD-Rat GH-RP-1/h per mg wet wt.) 3.49±0.29 (14) 3.96±0.38 (14) 2.66± 0.25 (9) 3.12±0.30 (9) 3.12±0.23 (14) 3.02± 0.27 (14) 2.54±0.24 (9) 2.44±0.22 (9) 3.37±0.21 (25) 3.10± 0.17 (25) 3.26±0.37 (17) 3.10±0.30 (17) 3.56±0.32 (7) 3.75± 0.25 (7) 3.40±0.30 (12) 4.57±0.36 (12) presence of dibutyryl cyclic AMP. In these experiments, the dibutyryl derivative of the cyclic nucleotide was added to both the control and experimental flasks at a concentration (0.2mM) previously shown to produce a significant but submaximal stimulation of hormone release (Table 4 ). This concentration of the stimulant was chosen so that both inhibition or further stimulation of release by the additions to the experimental flasks would be detectable. The results of these experiments are shown in Table 5 from which it can be seen that growth hormone output in the presence of the cyclic nucleotide and L-arginine hydrochloride was not significantly greater than output in the presence of the cyclic nucleotide alone. Low (2mM) and high (20mM) glucose concentrations, Ll-p-hydroxybutyrate (5mM) and albumin-bound palmitate (0.6mM) likewise didnotinfluence the rate ofgrowthhormone output in response to dibutyryl cyclic AMP (Table 5) . Effect of metabolic inhibitors and colchicine on control and cyclic AMP-stimulated growth hormone release. In an attempt to define the metabolic requirements necessary for the stimulating effect of cyclic AMP to occur, a series of experiments was carried out in which the effects of a number of metabolic inhibitors on the response to the cyclic nucleotide were investigated. The results (Table 6) show that, of the inhibitors tested, 2,4-dinitrophenol (0.2mM), 2-deoxyglucose (IlmM) and iodoacetate (0.4mM) all led to a significant decrease in the characteristic stimulation of release seen in the presence of 1mM-dibutyryl cyclic AMP. In contrast, malonate (8mM) led to a small but significant stimulation of both control release and release in the presence of dibutyryl cyclic AMP but did not significantly alter the magnitude of the secretory response to the cyclic nucleotide (Table 6 ). The effect of colchicine (0.1mM) on growth hormone output was also investigated. Table 6 shows that this agent led to small increases in both control and cyclic AMP-stimulated release, the latter effect being greater so that the apparent response to the cyclic nucleotide was also increased. None of these changes, however, was statistically significant.
DISCUSSION
Growth hormone release in the early and late phases of incubation. The finding that growth hormone release from isolated rat pituitary fragments in vitro was initially rapid was not unexpected and could have been attributed to non-specific leakage from cells damaged during the isolation or incubation procedures. However, both the duration of this accelerated release and its apparently exponential decay over the first 2 h of incubation did not seem to accord with this explanation. For this reason, it seemed possible that hormone release 822
1971 Table 5 . Effect of L-arginine hydrochloride, variations in glucose concentration, L-/3-hydroxybutyrate and albumin-bound palmitate on dibutyryl cyclic AMP-stimulated growth hormone release in vitro After preincubation for 2.5h, pituitary fragments were incubated for 1 h in 3ml of a bicarbonate buffered medium. All media contained bovine plasma albumin (1 mg/ml) and glucose (5.6mM), except where otherwise stated, together with dibutyryl cyclic AMP (0.2mM). Other additions to the medium were as shown. The results are expressed as the mean rates of hormone release (±S.E.M.) calculated for the number of observations in parentheses. Values of P for differences of the results from the appropriate control were calculated as described in the Materials and Methods section. Table 1 , the calculated secretory component in the early-phase studies is equal to 2.40±0.33 (mean+ S.E.M.) ,ug-equiv. of NIAMD-Rat GH-RP-1/h per mg wet wt. of tissue. In the absence of any external agent, this secretory component may be attributable to the residual activity of a stimulus in vivo, possibly the hypothalamic growth hormone releasing factor, the effects of which decay in vitro over a period of 2h after removal of the gland from the animal.
The demonstration of an endogenous stimulus during the first 2h of incubation in vitro suggested that the early phase of incubation was unsuitable for the further investigation of the regulation of growth hormone secretion. The greater sensitivity of the gland fragments to the stimulating effect of theophylline in the late phase than that seen in the early phase confirmed this view and a 2.5h-period of preincubation was therefore adopted in the remaining studies. Despite the extended duration of the resultant incubationin vitro, the viability of the tissue appeared to be unimpaired. Thus it was possible to demonstrate that both 02 uptake and the incorporation of labelled amino acids into newly synthesized growth hormone by the gland fragments proceeded at a constant rate over a period of up to 5h in vitro (R. B. Lockhart Ewart, unpublished work). In the context of the present studies, further evidence for the continuing viability of the preparation is provided by the results in Table 3 . These indicate that the response of the gland fragments to theophylline during the late phase of incubation shows the properties of calcium and energy dependence characteristic of a true secretory process.
Comparison with other preparations of anterior Vol. 124 Table 6 . Effect of 2,4-dinitrophenol, 2-deoxyglucose, iodoacetate, malonate and colchicine upon control and dibutyryl cyclic AMP-stimulated growth hormone release in vitro After preincubation for 2.5h, pituitary fragments were incubated for 1 h at 370C in 3 ml of a bicarbonate buffered medium containing bovine plasma albumin (1 mg/ml) and glucose (5.6mm (Birge, Peake, Mariz & Daughaday, 1967; Steiner et al. 1970) . In more extensive comparisons with the bovine pituitary slice system described in detail by Schofield (1967a) Tables 4 and 5 , however, it is clear that these agents are ineffective in modifying growth hormone release both from control and from cyclic AMP-stimulated fragments. Of particular note was the failure of low glucose concentration and of arginine, both of which are powerful stimuli to growth hormone secretion in man, significantly to increase the rate of hormone release from the rat pituitary in vitro. This finding might be explained by postulating a hypothalamic site of action for these stimuli in the rat. However, Garcia & Geschwind (1968) have reported that insulininduced hypoglycaemia in the rat and the administration of arginine to the rabbit lead either to no change or even to a fall in circulating growth hormone concentrations in these animals. Thus, an alternative explanation for the present findings is that they reflect a difference in the responsiveness of the pituitary cells from different species to a number of stimuli.
Role of cyclic AMP in the regulation of growth hormone secretion. In the present studies, the demonstration of a concentration-related stimulation of growth hormone release by both theophylline and dibutyryl-cyclic AMP is in marked contrast with the lack of effect of other metabolites and suggests a major role for cyclic AMP in (Henion, Sutherland & Posternak, 1967) . The remaining results in the present paper provide further evidence concerning the nature of cyclic AMP-mediated growth hormone secretion. Thus, it is known that the secretion of both luteinizing hormone (Samli & Geschwind, 1968) and thyroid-stimulating hormone (Vale, Burgus & Guillemin, 1968) are independent of protein synthesis de novo. In the present studies, with cycloheximide at a concentration previously shown to result in a 90% or greater inhibition of pituitary protein synthesis (R. B. Lockhart Ewart, unpublished work), it was possible to demonstrate that, in the case of growth hormone also, secretion requires neither synthesis of the hormone itself nor of any specific protein concerned in the secretory process over the period of observation.
In the past, there has been some debate as to whether or not energy may be necessary for the secretion of anterior pituitary hormones to occur in response to stimuli. Thus, the secretion of thyroid-stimulating hormone in response to its releasing factor has been reported to depend on a source of metabolic energy (Wilber & Utiger, 1968) . Samli & Geschwind (1968) , however, were unable to demonstrate an effect of 2,4-dinitrophenol on secretion of luteinizing hormone and a similar lack of effect of cyanide on luteinizing hormone secretion has been reported subsequently by Geschwind (1971) . In a recent publication Schofield & Stead (1971) have demonstrated a correlation between the rate of K+-stimulated growth hormone release from bovine pituitary slices incubated in vitro and changes in pituitary concentrations of ATP observed in the presence of uncouplers of oxidative phosphorylation. In the present studies, 2,4-dinitrophenol led to significant inhibition of growth hormone secretion in response to both theophylline and to cyclic AMP in addition to its effect in suppressing the secretion attributed to stimulation by endogenous releasing factor. In this respect, growth hormone secretion resembles that from many other exocrine and endocrine glands in that the process is dependent on a source of metabolic energy. Moreover, the present finding that 2,4-dinitrophenol inhibits the response to cyclic AMP as well as to releasing factor and theophylline, implies that ATP is not required simply as a substrate in the adenyl cyclase-catalysed generation ofcyclic AMP within the pituitary cells but that it is necessary at some later stage ofthe secretory process.
The results in Table 6 further indicate that 2-deoxyglucose and iodoacetate markedly inhibit the pituitary response to cyclic AMP. At the concentration used, these agents would be expected to inhibit glycolysis and we therefore infer that the response to the cyclic nucleotide is dependent on the integrity of the glycolytic pathway, presumably as a first step towards the provision of energy. The failure of 8mm-malonate to inhibit growth hormone secretion might imply that the operation of the tricarboxylic acid cycle is not essential for secretion to occur. However, it has to be conceded that there are many uncertainties about the role of malonate as a metabolic inhibitor (Webb, 1966b). Up to this point, the results presented are consistent with the currently accepted mechanism by which peptide hormone secretion is thought to occur (for review, see Fawcett, Long & Jones, 1969) . This involves the storage of newly synthesized hormone in membrane-limited intracytoplasmic granules, the contents ofwhich are extruded into the pericapillary spaces by exocytosis during the process of secretion. According to this scheme, secretion depends on the migration of the storage granules to the cell periphery for discharge. The present results suggest that this process may be specifically triggered by cyclic AMP, the generation of which in vivo is presumably brought about by activation of the adenyl cyclase of the growth hormone-secreting celLs by the, specific hypothalamic releasing factor. How cyclic AMP may act to cause such granule movement remains obscure. However, Goodman, Rasmussen, DiBella & Guthrow (1970) have proposed a unifying hypothesis to account for cyclic AMP-stimulated secretory processes in which they invoke the cyclic nucleotide as an activator, together with Ca2+, of a contractile microtubular system. That such a process may be involved in endocrine function is suggested by the observations that the secretion of both insulin (Lacy, Howell, Young & Fink, 1968) and thyroid hormones (Williams & Wolff, 1970) are inhibited by colchicine, an agent known to cause disaggregation of microtubules. In the present study, the failure to demonstrate inhibition of cyclic AMP-stimnulated secretion by colchi- 
